City Therapeutics, Inc. (CTY) Stock Statistics & Valuation Metrics

City Therapeutics, Inc. has a market cap or net worth of $1.08B. The enterprise value is ―.

City Therapeutics, Inc. has 50,332,280 shares outstanding. The number of shares has decreased by -2.65% in one year.

City Therapeutics, Inc.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of City Therapeutics, Inc. is ―. City Therapeutics, Inc.’s PEG ratio is 0.00.

In the last 12 months, City Therapeutics, Inc. had revenue of 8.16B and earned 1.83B in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was 3.31B and capital expenditures -1.14B, giving a free cash flow of 2.17B billion.

City Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

City Therapeutics, Inc. upcoming earnings date is ―, ―.

City Therapeutics, Inc. as a current ratio of ―, with Debt / Equity ratio of 58.82%

In the past 12 months, City Therapeutics, Inc. has paid 641.00M in taxes.

City Therapeutics, Inc. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

City Therapeutics, Inc. has $5.00M in cash and marketable securities with $4.66B in debt, giving a net cash position of -$4.66B billion.

Gross margin is 70.11%, with operating margin of ―, and net profit margin of ―.

The average price target for City Therapeutics, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―